Sight Sciences (NASDAQ:SGHT) Announces Earnings Results

Sight Sciences (NASDAQ:SGHT) issued its quarterly earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12), FiscalAI reports. Sight Sciences had a negative return on equity of 42.41% and a negative net margin of 32.13%. The firm had revenue of $24.92 million during the quarter, compared to the consensus estimate of $23.55 million.

Here are the key takeaways from Sight Sciences’ conference call:

• Sight Sciences reported record third-quarter revenue of $24.9 million, up 25% year over year, and raised 2026 revenue guidance to $92 million–$93 million, implying about 20% growth. Adjusted operating expense guidance was maintained at $92 million–$94 million.
• IDE revenue reached a record $3.9 million, up 45% sequentially, prompting the company to raise its full-year IDE outlook to approximately $12 million. Ordering accounts and utilization both increased, though TearCare growth remains concentrated in a limited reimbursed footprint and broader payer access is not yet assured.
• IG revenue grew 7% to $21 million, with active accounts at a record high; full-year IG guidance was raised to $80 million–$81 million. The company launched its next-generation OMNI Ultra in the U.S. and said expanded Aetna coverage adds about 25 million covered lives.
• Cash used in the quarter fell to $2.4 million from $9.1 million a year earlier, while year-to-date cash use improved 48%; the company ended the quarter with $77.4 million in cash. Management said it remains focused on cash-flow breakeven and extended the debt interest-only period through August 2027.

Sight Sciences Stock Up 1.1%

Shares of NASDAQ SGHT traded up $0.11 during midday trading on Friday, hitting $9.87. 140,893 shares of the stock traded hands, compared to its average volume of 277,769. The company has a debt-to-equity ratio of 0.58, a quick ratio of 4.67 and a current ratio of 4.95. Sight Sciences has a one year low of $3.38 and a one year high of $10.31. The business has a 50 day moving average price of $8.68 and a two-hundred day moving average price of $6.07. The company has a market cap of $543.72 million, a PE ratio of -18.98 and a beta of 2.44.

Insider Transactions at Sight Sciences

In other Sight Sciences news, CFO James Rodberg sold 7,208 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $8.85, for a total transaction of $63,790.80. Following the completion of the sale, the chief financial officer owned 216,829 shares in the company, valued at approximately $1,918,936.65. The trade was a 3.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Paul Badawi sold 29,653 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total transaction of $268,359.65. Following the transaction, the chief executive officer owned 6,092,819 shares in the company, valued at approximately $55,140,011.95. The trade was a 0.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 47,646 shares of company stock valued at $429,157 in the last 90 days. 30.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

SGHT has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a report on Wednesday. Wall Street Zen upgraded shares of Sight Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. HC Wainwright initiated coverage on shares of Sight Sciences in a research note on Thursday, October 15th. They issued a “buy” rating and a $14.00 price objective for the company. Piper Sandler reiterated an “overweight” rating and set a $12.00 target price (up from $9.00) on shares of Sight Sciences in a research report on Thursday. Finally, UBS Group increased their target price on shares of Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Sight Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.62.

Sight Sciences Company Profile

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.